Myriad Genetics Stock Forecast, Price & News

+0.38 (+1.22 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume428,302 shs
Average Volume646,845 shs
Market Capitalization$2.44 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

Myriad Genetics logo

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.52 out of 5 stars

Medical Sector

1101st out of 2,220 stocks

Diagnostic Substances Industry

19th out of 38 stocks

Analyst Opinion: 0.9Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

Is Myriad Genetics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Myriad Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View analyst ratings for Myriad Genetics
or view top-rated stocks.

What stocks does MarketBeat like better than Myriad Genetics?

Wall Street analysts have given Myriad Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Myriad Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a increase in short interest in July. As of July 15th, there was short interest totaling 6,310,000 shares, an increase of 18.4% from the June 30th total of 5,330,000 shares. Based on an average daily trading volume, of 571,400 shares, the days-to-cover ratio is currently 11.0 days. Approximately 8.4% of the shares of the stock are short sold.
View Myriad Genetics' Short Interest

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Myriad Genetics

How can I listen to Myriad Genetics' earnings call?

Myriad Genetics will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-633-8284.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its earnings results on Sunday, May, 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.09. The business had revenue of $173.10 million for the quarter, compared to the consensus estimate of $155.36 million. Myriad Genetics had a negative trailing twelve-month return on equity of 7.33% and a negative net margin of 27.26%. Myriad Genetics's quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) earnings per share.
View Myriad Genetics' earnings history

How has Myriad Genetics' stock been impacted by Coronavirus?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MYGN shares have increased by 125.4% and is now trading at $31.63.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MYGN?

5 equities research analysts have issued twelve-month price targets for Myriad Genetics' stock. Their forecasts range from $18.00 to $33.00. On average, they anticipate Myriad Genetics' stock price to reach $25.33 in the next twelve months. This suggests that the stock has a possible downside of 19.9%.
View analysts' price targets for Myriad Genetics
or view top-rated stocks among Wall Street analysts.

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. Paul J. Diaz, CEO, Pres & Director (Age 59, Pay $1.99M)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 50, Pay $817.32k)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 62, Pay $695.32k)
  • Mr. Mark S. Verratti, Pres of Myriad Neuroscience & Autoimmune (Age 53, Pay $560.7k)
  • Ms. Nicole Lambert, Pres of Myriad Genetic Laboratories, Women's Health, Oncology & International (Age 47, Pay $635.47k)
  • Dr. Kevin Richard Haas, Chief Technology Officer (Age 35)
  • Mr. Scott Gleason, Sr. VP of Investor Relations
  • Dr. Clivetty Martinez, Chief Compliance Officer
  • Mr. Jeff Borcherding, Sr. VP & Chief Marketing Officer
  • Ms. Jayne Baird Hart, Chief People Officer (Age 61)

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics CEO Paul Diaz on Paul Diaz has an approval rating of 74% among Myriad Genetics' employees.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.16%), Texas Permanent School Fund (0.07%), Fisher Asset Management LLC (0.07%), State of Alaska Department of Revenue (0.07%), Hillsdale Investment Management Inc. (0.05%) and Integrated Investment Consultants LLC (0.02%). Company insiders that own Myriad Genetics stock include Alexander Ford, Bernard Tobin, Daniel K Spiegelman, Gary A King, Jayne B Hart, Jerry S Lanchbury, John T Henderson, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Integrated Investment Consultants LLC, and Fisher Asset Management LLC. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Daniel K Spiegelman, Jayne B Hart, Jerry S Lanchbury, Nicole Lambert, and Paul Parkinson.
View insider buying and selling activity for Myriad Genetics
or view top insider-selling stocks.

Which major investors are buying Myriad Genetics stock?

MYGN stock was acquired by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., GWM Advisors LLC, Alliancebernstein L.P., State of Alaska Department of Revenue, and Texas Permanent School Fund. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, S Louise Phanstiel, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics
or or view top insider-buying stocks.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $31.63.

How much money does Myriad Genetics make?

Myriad Genetics has a market capitalization of $2.44 billion and generates $638.60 million in revenue each year. The company earns $-44,200,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Myriad Genetics have?

Myriad Genetics employs 2,700 workers across the globe.

Does Myriad Genetics have any subsidiaries?

The following companies are subsidiares of Myriad Genetics: AssureRx Canada Ltd, Assurex Health Inc., Crescendo Bioscience, Crescendo Bioscience Inc, Javelin Pharmaceuticals, MVZ Fur Molekulardiagnostik GmbH, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad RBM Inc., Myriad Services GmbH, Myriad Women’s Health, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, Rules-Based Medicine, and Sividon Diagnostics.

When was Myriad Genetics founded?

Myriad Genetics was founded in 1991.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is

Where are Myriad Genetics' headquarters?

Myriad Genetics is headquartered at 320 WAKARA WAY, SALT LAKE CITY UT, 84108.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.